Malignancy Ups Risk of Post-Hysterectomy Readmission

This article originally appeared here.
Share this content:
Malignancy Ups Risk of Post-Hysterectomy Readmission
Malignancy Ups Risk of Post-Hysterectomy Readmission

MONDAY, May 9, 2016 (HealthDay News) -- Risk factors have been identified for 30-day readmission following hysterectomy, according to a study published in the May issue of the American Journal of Obstetrics & Gynecology.

Malinda S. Lee, M.D., from Brigham and Women's Hospital/Massachusetts General Hospital in Boston, and colleagues examined risk factors for 30-day readmission following hysterectomy for 1,649 women with nongravid hysterectomies conducted from 2008 through 2010 (1,009 for benign indications and 640 for malignancy).

The researchers found that 6 percent of the women were readmitted within 30 days, with a mean time to readmission of 13 days. For women undergoing hysterectomy with benign indications, the odds of readmission were increased with a history of a laparotomy (including cesarean delivery) (adjusted odds ratio [aOR], 2.12) and a perioperative complication (aOR, 2.41). For women undergoing hysterectomy for malignancy, the odds of readmission were increased with an American Society of Anesthesiologists Physical Status Classification of III or IV (aOR, 1.92), a longer length of initial hospitalization (three days: aOR, 7.83), and an estimated blood loss of >500 mL (aOR, 3.29); the risk of readmission was reduced for women who underwent a laparoscopic hysterectomy (aOR, 0.32) and for those who were discharged on postoperative day one (aOR, 0.16).

"These findings can serve to develop interventions to allow gynecologic surgeons to appropriately stratify patients at highest risk for readmission at the time of hysterectomy," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

ASH: Synthetic Blood Cell Passes Proof-of-Concept Testing

ASH: Synthetic Blood Cell Passes Proof-of-Concept Testing

Synthetic product made from purified human hemoglobin proteins coated with a synthetic polymer

Fewer School Shootings in States With Tighter Gun Laws

Fewer School Shootings in States With Tighter Gun ...

Study also found that states that spent more money on mental health care, education saw less violence

SABCS: No Survival Benefit Seen for Letrozole Beyond Five Years

SABCS: No Survival Benefit Seen for Letrozole Beyond ...

Study found women who continued with letrozole did experience other benefits, however

is free, fast, and customized just for you!

Already a member?

Sign In Now »